AR and prostate carcinoma: IL-23 produced by myeloid-derived suppressor cells (MDSCs) stimulate AR in prostate cancer cells in order to promote survival and proliferation during androgen deprivation therapy (ADT) and, therefore, promote progression to CRPC.